Expression of BAF57 in ovarian cancer cells and drug sensitivity

Cancer Science

Takahiro Yamaguchi³  Tomoko Kurita⁵  Kazuto Nishio⁴  Junichi Tsukada³  Toru Hachisuga⁵  Yasuo Morimoto¹  Yoshiko Iwai² 

[1]Department of Occupational Pneumology, University of Occupational and Environmental Health, Kitakyushu, Japan

[2]Department of Molecular Biology, University of Occupational and Environmental Health, Kitakyushu, Japan

[3]Hematology, University of Occupational and Environmental Health, Kitakyushu, Japan

[4]Department of Genome Biology, Kinki University Faculty of Medicine, Kinki University, Higashiosaka, Japan

[5]Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Kitakyushu, Japan

关键词: Anticancer agents;    BAF57;    BCRP;    cell cycle;    chemotherapy;   

DOI  :  10.1111/cas.12612

来源: Wiley

【 摘 要 】

Abstract

The SMARCE1 (SWI / SNF-related, matrix-associated, and actin-dependent regulator of chromatin, subfamily e, member 1) encodes BAF57 protein. Previously, we reported that BAF57 is a predictive marker of endometrial carcinoma. In this study, we investigated BAF57 expression in ovarian cancer cell lines and their sensitivities to cisplatin, doxorubicin, paclitaxel, and 5-fluorouracil. BAF57 expression was strongly correlated with sensitivities to cisplatin, doxorubicin, and 5-fluorouracil in 10 ovarian cancer cell lines. Paclitaxel sensitivity was also correlated with BAF57 expression, but without significance. In A2780 ovarian cancer cells, knockdown of BAF57 using specific siRNA increased cell cycle arrest at G₁ phase and the sensitivities to these anticancer agents. cDNA microarray analysis of A2780 cells transfected with BAF57 siRNA showed that 134 genes were positively regulated by BAF57, including ATP-binding cassette, sub-family G (WHITE), member 2 (ABCG2) encoding breast cancer resistance protein (BCRP). We confirmed that knockdown of BAF57 decreased BCRP expression in ovarian cancer cells by Western blot analysis, and that ABCG2 gene expression might be regulated transcriptionally. These results suggested that BAF57 is involved in ovarian cancer cell growth and sensitivity to anticancer agents, and that BAF57 may be a target for ovarian cancer therapy.

【 授权许可】

CC BY-NC-ND   
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.